BioNTech SE (NASDAQ:BNTX - Get Free Report)'s stock price was up 1.3% on Thursday . The company traded as high as $121.24 and last traded at $120.84. Approximately 80,496 shares were traded during trading, a decline of 90% from the average daily volume of 806,855 shares. The stock had previously closed at $119.34.
Wall Street Analysts Forecast Growth
Several analysts have recently issued reports on BNTX shares. Deutsche Bank Aktiengesellschaft increased their target price on BioNTech from $95.00 to $150.00 and gave the stock a "buy" rating in a report on Thursday, September 19th. The Goldman Sachs Group upgraded shares of BioNTech from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $90.00 to $137.00 in a research note on Friday, November 8th. Jefferies Financial Group upgraded shares of BioNTech from a "hold" rating to a "buy" rating and boosted their target price for the company from $96.00 to $150.00 in a research report on Tuesday, September 17th. JPMorgan Chase & Co. cut their price target on shares of BioNTech from $124.00 to $122.00 and set a "neutral" rating for the company in a report on Tuesday, November 26th. Finally, Morgan Stanley raised shares of BioNTech from an "equal weight" rating to an "overweight" rating and lifted their price objective for the company from $93.00 to $145.00 in a research note on Tuesday, September 24th. Four analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, BioNTech has an average rating of "Moderate Buy" and an average price target of $140.76.
Check Out Our Latest Analysis on BioNTech
BioNTech Stock Up 1.1 %
The firm has a 50-day simple moving average of $113.91 and a 200 day simple moving average of $100.17. The stock has a market capitalization of $28.93 billion, a P/E ratio of -57.47 and a beta of 0.22. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21.
BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business had revenue of $1.24 billion during the quarter, compared to analyst estimates of $514.08 million. During the same quarter last year, the business earned $0.73 EPS. The firm's quarterly revenue was up 38.9% on a year-over-year basis. On average, equities research analysts forecast that BioNTech SE will post -3.72 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Candriam S.C.A. lifted its position in shares of BioNTech by 261.2% in the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company's stock worth $46,526,000 after purchasing an additional 418,695 shares during the period. Fred Alger Management LLC bought a new position in BioNTech during the third quarter worth $59,485,000. Baillie Gifford & Co. lifted its holdings in BioNTech by 0.4% in the third quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company's stock valued at $986,750,000 after buying an additional 31,773 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in BioNTech by 63.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 18,939 shares of the company's stock valued at $2,249,000 after acquiring an additional 7,340 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in BioNTech by 123.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 134,036 shares of the company's stock worth $15,919,000 after acquiring an additional 74,119 shares during the period. 15.52% of the stock is owned by institutional investors and hedge funds.
About BioNTech
(
Get Free Report)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
See Also
Before you consider BioNTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.
While BioNTech currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
